The Fed came very close to promising a rate cut Wednesday, and now markets are focused on a possible July rate cut.Market Insiderread more
Markets had expected the central bank to keep its benchmark interest rate steady while setting up a cut at the July meeting.The Fedread more
Powell said policymakers are concerned about some of the recent economic developments and see a growing case for easier policy.The Fedread more
Amazon and Blue Origin founder Jeff Bezos gave more insight into his space company's lunar plans on Wednesday.Technologyread more
As the presidents of U.S. and China near a highly anticipated meeting on trade, the gap in both sides' expectations regarding a deal remains wide.World Politicsread more
Delta warned travelers that a technical problem could delay flights on Wednesday.Airlinesread more
The Fed chief said that despite reports that Trump was looking to demote or fire him, he doesn't plan on leaving anytime soon.The Fedread more
If the Trump administration and Congress fail to reach a spending agreement, the White House will offer to keep the government funded at its current levels for a year, Mnuchin...Politicsread more
With bold and targeted steps, economists say, government can increase opportunity and incomes for many more people in ways that strengthen, not weaken, American capitalism.Politicsread more
Investors need to be cautious because the economy will get hurt the longer the trade war drags on, Jim Cramer says.Mad Money with Jim Cramerread more
Slack Technologies' reference price was set at $26 per share, the New York Stock Exchange announced Wednesday evening.Technologyread more
Blood-testing start-up Theranos took a number of management missteps that led to its most recent tangle with health regulators, business school professors said Thursday on CNBC's "Power Lunch. "
For several months, federal health regulators have raised concerns about the accuracy of the company's blood-testing technology. On Wednesday, The Wall Street Journal reported that the Centers for Medicare and Medicaid Services threatened to impose stiff sanctions on the company — including a ban that could prohibit Theranos CEO Elizabeth Holmes from owning or running a lab for at least two years.
In an interview with CNBC, Theranos spokesperson Brooke Buchanan stressed that the company is actively working to address issues raised by regulators.
"Elizabeth Holmes has not been banned from the industry, she hasn't been banned from Theranos and we continue to work hard to address all the concerns that have been raised by CMS," Buchanan said. "We're in constant communication with the regulators."
News of the potential sanctions against Theranos was not surprising, Bill George, a Harvard Business School professor and CNBC contributor, said on "Power Lunch."
"Theranos has never been forthcoming about its test results," George said.
There were other warning signs, too, said Jeff Sonennfeld, senior associate dean of the Yale School of Management.
"They've gone through some traumatic changes in board governance," Sonnenfeld said, noting that the company at one point counted former U.S. Sen. Bill Frist, former Secretary of State George Shultz, and Henry Kissinger as board members.
Any sanction CMS decides to impose on Theranos would likely meet a lengthy appeal process, the Journal reported Wednesday.
If Theranos is ultimately sanctioned, however, it could spell out the company's demise, George said.
"This is very, very serious," he said.